Lutathera Shows Promise as Part of Initial Therapy for Some Neuroendocrine Tumors - Cancer Currents Blog

The latest from the NCI Cancer Currents blog

Having trouble viewing this email? View it as a Web page.

Lutathera Shows Promise as Part of Initial Therapy for Some Neuroendocrine Tumors 03/01/2024 Adding Lu 177-dotate to the initial treatment of certain advanced neuroendocrine tumors nearly tripling the length of time people survive without their tumors getting worse, according to new clinical trial results. You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp  Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892